MedTrace Logo

Fascia Iliaca Compartment Block for Proximal-end Femur Fractures

NCT02696915 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-03-08

No results posted yet for this study

Summary

Fracture femur is a common injury which is associated with excruciating pain. Positioning for neuraxial blocks is always challenging because even slight overriding of the fracture ends is intensely painful .It can causing major patient distress which accompanied by well-known physiological sequelae such as sympathetic activation causing tachycardia, hypotension, and increased cardiac work that may compromise high-risk cardiac patients.

Fascia iliaca compartment block is highly effective in blocking lateral cutaneous nerve of the thigh and femoral nerve. Fascia iliaca compartment block is not only easy to perform but it is also associated with minimal risk as the local anesthetic is injected at a safe distance from the femoral artery and femoral nerve. It is always safe to perform the fascia iliaca compartment block prior to spinal anesthesia as the patient can respond during administration of the local anesthetic and can prevent intra-neuronal injections

Conditions

  • Proximal Femur Fractures

Interventions

DRUG

Placebo

Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml

DRUG

Bupivacaine

Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml

DEVICE

Ultrasound guided fascia iliaca compartment block

Ultrasound guided fascia iliaca compartment block

DRUG

Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)

Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Reem A El Sharkawy, MD · Lecturer of Anesthesia and Surgical Intensive Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02696915 on ClinicalTrials.gov